An interventional study of Hyperspectral camera in Dementia and Alzheimer Disease, sponsored by Center for Eye Research Australia. Terminated at 1 site in Australia. Open to participants aged 30 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by Center for Eye Research Australia · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 177 studies in Alzheimer Disease with a site in Australia — 23 open to participants now, 42 under way, 18 of them phase 3. Alzheimer Disease · Australia.
Among the 177 studies in Alzheimer Disease with a site in Australia, this one is the 109th largest by enrollment of the 168 interventional ones that give a count, is one of 10 that started in 2016, is one of 9 with no phase, and was the 170th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →23 of the 177 studies in Alzheimer Disease with a site in Australia are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Australia, United States, France and 2 more countries
Ages 50–90
Hoffmann-La Roche · Sites in Australia, United States, Argentina and 7 more countries
Ages 55–80
Acta Pharmaceuticals · Sites in Australia
Ages 18–55 · Healthy volunteers
Sanofi · Sites in Australia, United States, Canada and 4 more countries
Ages 55–85
ChainGen Biopharma Ltd · Sites in Australia
Ages 18–55 · Healthy volunteers
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 30 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
177 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 63 · Phase 3 83 · Phase 4 2
First in 1999; this study’s year is marked. 10 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 186 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 313 across the 168 interventional studies, 1,000 across the 9 observational. Of the 130 that completed or were terminated, 69 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
153 of 177 have an industry lead sponsor. The 10 most frequent:
Center for Eye Research Australia is the lead sponsor of 12 studies on the registry; 6 are open to participants now.
Center for Eye Research Australia has 2 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
10 of the studies in Alzheimer Disease with a site in Australia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT06268886Bristol-Myers SquibbStudy to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease | 2026-12-17 |
| NCT06544616Janssen Pharmaceutica N.V., BelgiumA Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease | 2026-12-22 |
| NCT06339190Monash UniversityNeurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis | 2027-03 |
| NCT07660341ChainGen Biopharma LtdSAD Study of CGB3002 in Healthy Participants | 2027-04-30 |
Add all 10 to your calendar (.ics) → With an account.
Among the 177 studies in Alzheimer Disease with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hyperspectral retinal imaging is a non-invasive imaging modality in which a series of images of the retina are captured using light of different wavelengths. The resulting "hypercube" of data provides detailed information about retinal structure. Previous research has demonstrated a potential role for this technology in the detection of retinal amyloid beta in Alzheimer's disease. This study aims to further evaluate the use of hyperspectral retinal imaging in the assessment of individuals with dementia or those at risk of Alzheimer's disease.
The study involves retinal imaging using specialised cameras to capture detailed photographs of the eye. Imaging includes the use of two hyperspectral retinal cameras, which are similar to standard retinal cameras but use multi-wavelength (multicoloured) light instead of a conventional white-light flash.
These hyperspectral imaging devices are investigational and are not approved for routine clinical use in Australia. Their use in this research has been approved by the Human Research Ethics Committee of the Royal Victorian Eye and Ear Hospital following scientific and ethical review. The Therapeutic Goods Administration of Australia has been notified of their use under the Clinical Trial Notification (CTN) scheme.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
This study's enrollment of 186 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Center for Eye Research Australia is the lead sponsor of 12 studies on the registry; 6 are open to participants now.
Compared within Alzheimer Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dementia. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Device: Hyperspectral camera
Hyperspectral imaging is performed with the Metabolic Hyperspectral Retinal Camera (Optina Diagnostic, Montreal, Canada) and a prototype camera developed by researchers at the Centre for Eye Research Australia (CERA). The Metabolic Hyperspectral Retinal Camera is similar to a typical fundus imager but it incorporates a tunable light source which is able to transmit safe light levels within a wavelength range covering the visible to near infrared with a narrow bandwidth (\< 3nm). This instrument is capable of imaging a 26° field-of-view of retina at 90 wavelengths in less than a second, thus minimizing discomfort and limiting the influence of eye movements. The hyperspectral camera developed by CERA researchers is a non-mydriatic fundus camera that uses light emitting diodes (LEDs) and an optical variable bandpass filter to tune the illumination wavelengths.
Diagnostic performance of hyperspectral retinal imaging for detection of Alzheimer's disease-related beta-amyloid
Assessment of whether hyperspectral retinal imaging can distinguish participants with Alzheimer's disease from cognitively healthy controls based on retinal spectral reflectance signatures (particularly in the 480-520 nm wavelength range). Performance will be evaluated using quantitative image-derived biomarkers and classification accuracy (e.g., sensitivity, specificity, and area under the receiver operating characteristic curve) generated from computer-assisted image analysis.
Time frame: Single study visit (baseline imaging session; approximately 60 minutes)
Plan to share: Undecided — The plan for sharing individual participant data (IPD) has not yet been finalised. This is a multi-modal imaging study involving large hyperspectral and ophthalmic imaging datasets, and decisions regarding data sharing will depend on completion of primary analyses, data governance requirements, and ethical approvals. The feasibility of appropriate de-identification and secure sharing mechanisms is under review.
No publications or documents are linked to this record.
Ran from Feb 2016 to primary completion in Jan 2024, 95 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Center for Eye Research Australia